Tempus AI, Inc. (TEM)

NASDAQ: TEM · Real-Time Price · USD
47.56
+1.38 (2.99%)
May 26, 2026, 12:00 PM EDT - Market open
Market Cap8.54B -24.4%
Revenue (ttm)1.36B +69.8%
Net Income-302.91M
EPS-1.72
Shares Out 179.56M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume2,503,225
Open47.08
Previous Close46.18
Day's Range46.22 - 48.21
52-Week Range41.73 - 104.32
Betan/a
AnalystsBuy
Price Target67.20 (+41.3%)
Earnings DateMay 5, 2026

About TEM

Tempus AI, Inc. operates as a healthcare technology company in the United States. It offers the Tempus platform, a closed-loop, full-stack, bi-directional integrations between a clinician’s desktop and its laboratory diagnostic capabilities, analytics platform, and repository of multimodal data; and Hub, a clinical application for physicians and other healthcare providers for use in the diagnostics product line as an end-to-end application for healthcare providers for NGS tests. The company also provides Lens, a software application for life sc... [Read more]

Sector Healthcare
IPO Date Jun 14, 2024
Employees 3,800
Stock Exchange NASDAQ
Ticker Symbol TEM
Full Company Profile

Financial Performance

In 2025, Tempus AI's revenue was $1.27 billion, an increase of 83.41% compared to the previous year's $693.40 million. Losses were -$245.03 million, -67.12% less than in 2024.

Financial Statements

Analyst Summary

According to 17 analysts, the average rating for TEM stock is "Buy." The 12-month stock price target is $67.2, which is an increase of 41.30% from the latest price.

Price Target
$67.2
(41.30% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Tempus Announces 37 Abstracts Accepted for Presentation at the 2026 American Society of Clinical Oncology Annual Meeting

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced that 37 abstracts have been accepted for present...

3 hours ago - Business Wire

Tempus AI announces clinical launch of ArteraAI Prostate Test

Tempus AI (TEM) announced the clinical launch of the ArteraAI Prostate Test. The CLIA-certified and CAP-accredited prognostic test will be fully integrated into the Tempus platform, providing urologis...

5 days ago - TheFly

Tempus Launches ArteraAI Prostate Test for Metastatic Patients, Marking the First Prostate Digital Pathology Algorithm in the Tempus Ecosystem Available for Clinical Use

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc., a leader in artificial intelligence and precision medicine, today announced the clinical launch of the ArteraAI Prostate Test (mHSPC). The CLIA-certified and...

5 days ago - Business Wire

Tempus AI announces strategic collaboration with Bristol Myers

Tempus AI (TEM) announced a new initiative with Bristol Myers Squibb (BMY). This collaboration aims to leverage AI, multimodal real-world data and data science techniques to optimize clinical trial de...

Other symbols: BMY
12 days ago - TheFly

Tempus Expands Strategic Collaboration with Bristol Myers Squibb to Enhance the Probability of Success Across Clinical Development Programs In Oncology and Neuroscience

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced a new initiative with Bristol Myers Squibb (NYSE...

Other symbols: BMY
12 days ago - Business Wire

Cathie Wood’s ARK Investment buys 163K shares of Tempus AI today

20:02 EDT Cathie Wood’s ARK Investment buys 163K shares of Tempus AI (TEM) today

14 days ago - TheFly

Tempus AI price target lowered to $64 from $95 at H.C. Wainwright

H.C. Wainwright analyst Yi Chen lowered the firm’s price target on Tempus AI (TEM) to $64 from $95 and keeps a Buy rating on the shares. The firm cites the…

15 days ago - TheFly

Ambry Genetics' CARE Program® Wins 2026 MedTech Breakthrough Award for “Best Overall Health Informatics Solution”

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Ambry Genetics, a leader in clinical genomic testing, and a wholly owned subsidiary of Tempus AI, Inc. (NASDAQ: TEM), today announced that its CARE Program (Compr...

15 days ago - Business Wire

Tempus AI price target lowered to $80 from $90 at BTIG

BTIG lowered the firm’s price target on Tempus AI (TEM) to $80 from $90 and keeps a Buy rating on the shares. The firm cites a pullback in valuations in…

16 days ago - TheFly

Tempus Announces Pricing of Upsized Offering of $400.0 Million of Convertible Senior Notes

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (“Tempus”) (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced the pricing of $400....

18 days ago - Business Wire

Tempus AI announces proposed convertible senior notes offering

Tempus AI (TEM) announced its intent to offer, subject to market conditions and other factors, $350.0 million aggregate principal amount of Convertible Senior Notes due in 2032 in a private…

19 days ago - TheFly

Cathie Wood’s ARK Investment buys 146K shares of Tempus AI today

20:02 EDT Cathie Wood’s ARK Investment buys 146K shares of Tempus AI (TEM) today

19 days ago - TheFly

Tempus AI, Inc. Announces Proposed Convertible Senior Notes Offering to Optimize Capital Structure and Reduce Interest Expense

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (“Tempus”) (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced its intent to offer,...

19 days ago - Business Wire

Tempus AI price target lowered to $59 from $68 at Baird

Baird analyst Catherine Ramsey Schulte lowered the firm’s price target on Tempus AI (TEM) to $59 from $68 and keeps an Outperform rating on the shares. The firm updated its…

19 days ago - TheFly

Tempus AI price target raised to $68 from $65 at TD Cowen

TD Cowen raised the firm’s price target on Tempus AI (TEM) to $68 from $65 and keeps a Buy rating on the shares. The firm said its strong growth was…

19 days ago - TheFly

Lucent Diagnostics announces collaboration with Tempus AI

Lucent Diagnostics, a brand of Quanterix Corporation (QTRX), announced a collaboration with Tempus AI (TEM) to broaden access to a novel blood-based biomarker panel designed to improve detection accur...

Other symbols: QTRX
19 days ago - TheFly

Lucent Diagnostics Announces Collaboration with Tempus to Integrate Blood-Based Alzheimer's Biomarker Testing into Clinical Workflows

BILLERICA, Mass.--(BUSINESS WIRE)--Lucent Diagnostics, a brand of Quanterix Corporation (NASDAQ: QTRX), today announced a collaboration with Tempus AI Inc. (NASDAQ: TEM), a technology company leading ...

Other symbols: QTRX
20 days ago - Business Wire

Tempus AI reports Q1 adjusted EPS (13c), consensus (20c)

Reports Q1 revenue $348.1M, consensus $345.44M. “Our strong financial and operational performance this quarter underscores the accelerating demand for our AI-driven diagnostic platform and the immense...

20 days ago - TheFly

Tempus AI raises FY26 revenue view to $1.59B-$1.6B from $1.59B, consensus $1.59B

Backs FY26 adjusted EBITDA view roughly $65M.

20 days ago - TheFly

Tempus AI Earnings Call Transcript: Q1 2026

Revenue grew 36% year-over-year to $348.1 million, led by strong oncology and data businesses. Guidance was raised to $1.59–$1.6 billion in revenue and $65 million adjusted EBITDA for 2026, with robust growth in strategic pharma collaborations and improving cash flow expected.

20 days ago - Transcripts

Tempus AI Earnings release: Q1 2026

Tempus AI released its Q1 2026 earnings on May 5, 2026, summarizing the period's financial results.

20 days ago - Filings

Tempus AI Slides: Q1 2026

Tempus AI has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 5, 2026.

20 days ago - Filings

Tempus AI Quarterly report: Q1 2026

Tempus AI has published its Q1 2026 quarterly earnings report on May 5, 2026.

20 days ago - Filings

Tempus Reports First Quarter 2026 Results

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today reported financial results for the quarte...

20 days ago - Business Wire

Tempus to Host Inaugural Investor Day on May 29, 2026

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced that the company will host an Investor Day on Fr...

27 days ago - Business Wire